Results 31 to 40 of about 6,043 (288)

Bullous fixed drug eruption related to multivitamins [PDF]

, 2020
Multivitamins are commonly consumed over-the-counter supplements. Drug reactions related to multivitamins are rare and very few cases have been reported.
Jha, Niharika
core   +1 more source

Rabeprazole induced Fixed Drug Eruption: A rare case report

, 2017
Among cutaneous adverse drug reactions, fixed drug eruption is the most common cutaneous drug reaction among the Indian population. The drugsmost commonly implicated in fixed drug eruption are analgesics and antibiotics.
Balaji Ommurugan, Navin Patil, Amita Priya   +2 more
core   +2 more sources

Fixed drug eruption to erythromycin

Acta Dermato-Venereologica, 1984
A case of repeated eruption after administration of erythromycin is described. It is the first report of erythromycin as proven agent of such an allergic reaction.
P D, Pigatto, A, Riboldi, F, Riva, G F, Altomare   +3 more
openaire   +2 more sources

Fixed drug eruption to levocetirizine and cetirizine

Indian Journal of Dermatology, 2014
Lalit Kumar Gupta, Nidheesh Agarwal, Ashok Kumar Khare, Asit Mittal   +3 more
doaj   +3 more sources

Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features

, 2017
Background: Generalized bullous fixed drug eruption (GBFDE), a particular form of fixed drug eruption (FDE), is characterized by widespread blisters and erosions and can be confused with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
朱家瑜, Cho, Yung-Tsu;Lin, Jheng-Wei;Chen, Yi-Chun;Chang, Chia-Ying;Hsiao, Cheng-Hsiang;Chung, Wen-Hung;Chu, Chia-Yu   +1 more
core   +1 more source

Atomic Layer Deposition Processes: Versatile Platforms for Engineering ZnO‐Chitosan Biointerfaces

Advanced Healthcare Materials, EarlyView.
Vapour phase metalation (VPM), multiplied pulsed vapour phase infiltration (MPI), and O2 plasma‑enhanced atomic layer deposition (PEALD) tailor Zn–chitosan (Zn‑CS) films. PEALD improves wettability and biocompatibility. MPI enhances semiconductor behavior. Antiseptic selectivity: VPM → E. coli; MPI → H. pylori.
Mabel Moreno, Anjana Devi, David Zanders, Miryam Arredondo, Davide Mariotti, Ruairi McGlynn, Sindy Devis, Simón Guerrero, Eglantina Benavente, Matias Alegría, Yusser Olguin, Lorena Lobos‐Gonzalez, Kevin Guzmán, Elizabeth Rivas‐Yañez, Paula Solar, Valentin Cepus, Michael Krause, Luis Velásquez   +17 more
wiley   +1 more source

Bullous fixed drug eruption due to erlotinib: A rare case report

Annals of Oncology Research and Therapy
Fixed Drug Eruption is one of the most common cutaneous adverse drug reactions, of which the bullous variant is a more severe form. Epidermal growth factor (EGFR) inhibitors are one of the prime chemotherapeutic agents used recently in various ...
Kallolinee Samal, Manoj Kumar Nayak, Srigopal Mohanty, Nibedita Dixit   +3 more
doaj   +1 more source

Fixed drug eruption related to fluconazole [PDF]

, 2016
Fixed drug eruption (FDE) is a type of cutaneous drug reaction that occurs at the same sites upon re-exposure to specific medications.
Hsu, Sylvia, Lai, Olivia
core   +1 more source

Piroxicam‐induced fixed drug eruption in palatal mucosa

, 2021
Background: Fixed drug eruption is a drug reaction characterized by the recurrent occurrence of erosive or ulcerative lesions in skin or mucosa surfaces upon the use of a specific drug. The occurrence of fixed drug eruption in oral mucosa is rare and ill
Saygo Tomo, da Silva Cunha, John L., Simonato, Luciana E., da Silva Santos, Ingrid, Ingrid da Silva Santos, Luciana E. Simonato, Ana C. Prado Ribeiro, Tomo, Saygo, dos Santos Silva, Alan R., Miyahara, Glauco I. [UNESP], Prado Ribeiro, Ana C., John L. da Silva Cunha, Glauco I. Miyahara, Alan R. dos Santos Silva   +13 more
core   +1 more source

A Pragmatic Trial of a Shared Decision‐Making Intervention to Improve Medication Adherence and Outcomes in Systemic Lupus Erythematosus: The HCQ‐SAFE Study

Arthritis &Rheumatology, EarlyView.
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee, Jay J. Patel, Jessica Kent, Betty Chewning, Sancia Ferguson, Patricia Tellez‐Giron, David Gazeley, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source